GRI:NSD-GRI Bio Inc. (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 6.52

Change

+0.90 (+16.01)%

Market Cap

N/A

Volume

0.03M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-18 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

-1.53 (-0.30%)

USD 123.21B
REGN Regeneron Pharmaceuticals Inc

-13.46 (-1.98%)

USD 76.39B
ARGX argenx NV ADR

-3.01 (-0.49%)

USD 37.97B
ALNY Alnylam Pharmaceuticals Inc

-8.81 (-3.48%)

USD 31.94B
ONC BeiGene, Ltd.

-3.69 (-1.39%)

USD 28.70B
RPRX Royalty Pharma Plc

+0.39 (+1.18%)

USD 18.65B
SMMT Summit Therapeutics PLC

-0.30 (-1.49%)

USD 17.01B
UTHR United Therapeutics Corporatio..

-8.82 (-2.73%)

USD 14.37B
INCY Incyte Corporation

-2.01 (-3.24%)

USD 14.22B
MRNA Moderna Inc

-0.90 (-2.59%)

USD 13.74B

ETFs Containing GRI

UKPH:XETRA iShares UK Property UCITS.. 3.23 % 0.00 %

-0.02 (-0.48%)

N/A
IUKP:SW iShares UK Property UCITS.. 3.07 % 0.00 %

-0.03 (-0.48%)

USD 0.54B
IUKP:LSE iShares UK Property UCITS 0.00 % 0.00 %

-2.25 (-0.48%)

USD 0.54B
UKRE:LSE iShares MSCI Target UK Re.. 0.00 % 0.00 %

-2.55 (-0.48%)

USD 0.10B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -53.70% 9% A- 6% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return -53.70% 9% A- 6% D-
Trailing 12 Months  
Capital Gain -96.10% 4% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -96.10% 4% F 2% F
Trailing 5 Years  
Capital Gain -100.00% N/A F N/A F
Dividend Return N/A N/A N/A N/A N/A
Total Return -100.00% N/A F N/A F
Average Annual (5 Year Horizon)  
Capital Gain -39.64% 6% D- 3% F
Dividend Return -39.64% 6% D- 3% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 47.67% 66% D+ 40% F
Risk Adjusted Return -83.15% 11% F 6% D-
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector